Acceleron and Shire not to restart ACE-031 program
Privately-held US biotech firm Acceleron Pharma says that Ireland-headquartered Shire (LSE: SHP) has concluded its collaboration on ACE-031 and related molecules. The clinical development of ACE-031 was suspended in February 2011 and since then the companies have conducted preclinical studies to determine whether to resume clinical studies.
The companies have now decided not to restart the development of this program. Acceleron remains focused on the 11 Phase II clinical studies currently underway across its three investigational protein therapeutics - sotatercept, dalantercept and ACE-536 – in oncology and hematology.
Shire entered into a collaboration with Acceleron in 2010, paying an upfront $45 million for rights to develop and commercialize ACE-031 in Duchenne muscular dystrophy (DMD), in a deal that could have been worth as much as $500 million in total (The Pharma Letter September 10, 2010).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze